Atorvastatin in the TREATment of Intracranial Unruptured VertebroBasilar Dissecting Aneurysms

Summary

This study was designed to whether there is a measurable reduction in inflammation in walls of unruptured vertebrobasilar dissecting aneurysms with atorvastatin.

Timeline

Start

2021-07-01

Primary completion

2022-01-01

Completion

2022-07-30

Outcome

Met primary endpoint

paper The change in WEI was -0.3 in the statin group but 0.1 in the control group (P < .001). PMID 41432563 ↗

paper Similarly, the change in WEVR was -15.1% in the statin group but 5.3% in the control group (P < .001). PMID 41432563 ↗

Publications

• Zhang Y, Wang C, Dong L, Turhon M, Kang H, Liu J, Duan Y, Tian D, Sui B, Zhang Y, Wang K, Mossa-Basha M, Yang X, Zhu C. Statins Reduce Wall Enhancement at Vessel Wall MRI in Unruptured Vertebrobasilar Dissecting Aneurysms: A Randomized Controlled Trial. Radiology. 2025 Dec;317(3):e242806. doi: 10.1148/radiol.242806.
• Turhon M, Kang H, Huang J, Li M, Liu J, Zhang Y, Wang K, Yang X, Zhang Y. Atorvastatin for unruptured intracranial vertebrobasilar dissecting aneurysm (ATREAT-VBD): protocol for a randomised, double-blind, blank-controlled trial. BMJ Open. 2022 Apr 28;12(4):e059616. doi: 10.1136/bmjopen-2021-059616.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Atorvastatin	Small molecule	20 mg	Oral

Indications